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Dengue  represents  a  signiﬁcant  and  growing  public  health  problem  across  the globe,  with approximately
half  of the  world’s  population  at risk.  The  increasing  and  expanding  burden  of dengue  has  highlighted
the  need  for  new  tools  to  prevent  dengue,  including  development  of dengue  vaccines.  Recently,  the
ﬁrst  dengue  vaccine  candidate  was  evaluated  in  Phase  3 clinical  trials,  and  other  vaccine  candidates  areaccine development
under  clinical  evaluation.  There  are  also  a  number  of  candidates  in preclinical  development,  based  on
diverse  technologies,  with  promising  results  in animal  models  and  likely  to  move  into  clinical  trials  and
could  eventually  be next-generation  dengue  vaccines.  This  review  provides  an  overview  of  the various
technological  approaches  to dengue  vaccine  development  with  speciﬁc  focus  on candidates  in  preclinical
development  and  with evaluation  in non-human  primates.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Dengue is a mosquito-borne ﬂaviviral disease that has spread
o most tropical and many subtropical areas, creating a signiﬁcant
urden of disease and economic costs in endemic countries [1,2].
ne recent prediction of the global burden suggests approximately
90 million dengue infections each year (95% credible interval
84–528), of which 96 million (C.I. = 67–136) are clinically apparent
2]. To date, speciﬁc dengue therapeutics are not available and dis-
ase prevention is limited to vector control and personal protective
easures with little data to support their impact on clinical disease
3]. Thus, the development of a safe and effective dengue vaccine
ould represent a major advancement in the control of the disease.
ne candidate has been evaluated in Phase 3 trials in Asia and Latin
merica. The vaccine, a three-dose live recombinant tetravalent
engue vaccine based on the YF17D backbone (CYD-TDV), demon-
trated efﬁcacy in the ﬁrst year of the observation period (from 28
ays after the third dose) of 56.7% in Asia [4] and 60.8% in Latin
merica [5]. In longer-term hospital-based follow up, a signal of
ncreased risk of severe and hospitalized dengue was identiﬁed
n the 2–5 year age group in Asia, with a relative risk of hospital-
zed dengue in year 3 post-dose 1 of 7.45 (95% CI 1.15–313.80) [6].
he mechanism behind this increased risk is not understood [7],
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and the sponsor has recommended an indication for individuals 9+
years of age [8]. Second generation vaccines may  improve on the
range of the age indication, dose-scheduling, or efﬁcacy, as well as
contribute to vaccine supply security.
This is an update of a 2011 review focusing on dengue vaccine
candidates in preclinical development [9]. It is based on published
data and written updates solicited from vaccine developers and
researchers. Primary focus was  given to candidates who  are in
active development and have been evaluated in non-human pri-
mate (NHP) models (Table 1). The ﬁrst part of the review presents an
overview of dengue immunity, challenges to vaccine development
and the various technologies used, while the second part provides a
more detailed description of speciﬁc vaccine projects in preclinical
development.
2. Overview of dengue vaccine development
2.1. Dengue immunity and challenges to vaccine development
The disease dengue is caused by four serotypes of dengue
virus (DENV), DENV-1 to DENV-4. Multiple serotypes of DENVs
co-circulate in endemic areas [10]. Infection by one serotype
confers lasting protection against disease, and possibly infection,
following re-exposure to the same serotype, but only tran-
sient protection against secondary infection by one of the three
heterologous serotypes (reviewed in [11]). Dengue vaccine devel-
opment efforts therefore aim for a vaccine which simultaneously
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Table 1
Active dengue vaccine candidates in preclinical development that have been evaluated in NHP models.
Technological approach Vaccine developer Antigen Valency under evaluation
or evaluated in NHP
Recombinant subunit
vaccines
IPK/CIGB EDIII-p64k fusion proteins and EDIII-capsid fusion
proteins expressed in E. coli
Monovalent
VaxInnate Bivalent 80E-STF2 fusion proteins expressed in
baculovirus/insect cells
Tetravalent
NHRI Tetravalent consensus EDIII protein expressed in E. coli Tetravalent
DNA vaccines NMRC Tetravalent “shufﬂed” prM/E expressed from plasmid
vector
Tetravalent
CDC prM/E expressed from plasmid vector Tetravalent
VLP Vaccines ICGEB EDIII-HBsAg VLPs or ectoE-based VLPs expressed in P.
pastoris
Tetravalent
Virus-vectored vaccines Themis Bioscience/Institut
Pasteur
Tetravalent EDIII and DENV-1 ectoM expressed from
live-attenuated measles virus vector
Tetravalent
Global Vaccines E85 expressed from single-cycle VEE virus vector Tetravalent
Puriﬁed inactivated virus
vaccines
NMRC Psoralen-inactivated DENV Monovalent
WRAIR/GSK/FIOCRUZ Puriﬁed inactivated DENV Tetravalent
Global Vaccines Inactivated virus (+VEE-particle adjuvant) Tetravalent
Live attenuated virus
vaccines
Chiang Mai
University/Mahidol
University/NSTDA/BioNet-
Asia
DEN/DEN chimeric viruses Monovalent
Arbovax DEN host range mutations Tetravalent
Beijing Institute of
Microbiology and
Epidemiology
DEN-SA 14 14 2 Monovalent
Novartis Institute for
Tropical Diseases/Agency
for Science, Technology
and Research, Singapore
DEN targeted mutation (2′-O-methyltransferase
mutant)
Bivalent
Heterologous prime-boost
approaches
NMRC/WRAIR Puriﬁed inactivated DENV or plasmid vector expressing
prM/E (prime) and live attenuated DENV (boost)
Tetravalent
 prM/E
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rovides long-term protection against all DENV serotypes, and cur-
ent approaches focus on the development of tetravalent vaccines.
The mechanism of protective immunity against dengue is not
ully understood. There is considerable evidence for a major role
f antibody-mediated DENV neutralization in protection against
nfection and disease [11]. However, it is unclear what quantity
nd/or quality of neutralizing antibody is needed for protective
mmunity. Further support for this conclusion is the apparent dis-
ociation of the protective efﬁcacy of CYD-TDV and the elicited
irus-neutralizing antibody of individuals in vaccine clinical trials,
hen measured in Vero cell-based PRNT50 assays [12,13]. Recent
tudies have begun to better deﬁne the cell-speciﬁc characteristics
ssociated with in vitro virus-neutralization assays [14]. In addition,
ontributions of other immune mechanisms such as cytotoxic T cell
esponses are less clear (reviewed in [11,15]). Further research is
eeded to better deﬁne and validate immune correlates of protec-
ion for vaccine development.
Another challenge for vaccine development is the potentially
etrimental role of immune enhancement in dengue pathogen-
sis. Severe disease is most commonly observed in secondary,
eterologous DENV infections. Antibody-dependent enhancement
ADE) of infection has been proposed as the primary mecha-
ism of dengue immunopathogenesis [16–18]. In vitro studies
uggest that the capacity of DENV antibodies to contribute
o neutralization or enhancement of infection is determined
y multiple factors, including antibody speciﬁcity, antibody expressed from live attenuated chimeric
 virus with DNA vaccine
Monovalent
afﬁnity, antibody titre and epitope accessibility (reviewed in
[19,20]).
The potential risk of immune enhancement of infection and dis-
ease underscores the importance of developing dengue vaccines
which produce long-lasting immunity to all four DENV serotypes.
A tetravalent vaccine eliciting protective, neutralizing antibody
responses against all serotypes should address theoretical concerns
about vaccine-induced immune enhancement. However, vaccine-
induced immune enhancement might again become problematic
as antibody titres wane post-vaccination. The applicability of an
immune enhancement hypothesis to explain the latest results in
younger children in the CYD-TDV longer term follow up is unclear
with currently published data [6].
DEN virions are composed of a lipid envelope modiﬁed by the
insertion of envelope (E) proteins and premembrane/membrane
(prM/M) proteins (depending on the maturation state [21]), sur-
rounding a nucleocapsid composed of capsid (C) proteins and the
viral RNA genome (reviewed in [22]). Human antibodies raised
against the DEN virion are mostly targeted at the E and prM pro-
teins [23]. Research to determine the most suitable target epitopes
for vaccines is ongoing, and while considerable progress has been
made in the characterization of the humoral immune response
to DENV, important knowledge gaps still exist. There is evidence
suggesting that anti-E antibodies have higher type-speciﬁc neutral-
ization capacity and lower ADE potential than anti-prM antibodies.
Moreover, most potent DENV neutralizing murine monoclonal
ccine 3
a
I
o
a
s
a
a
a
u
i
w
s
h
d
i
c
d
a
d
t
a
N
t
u
a
d
D
a
i
e
p
t
i
a
c
m
s
t
d
t
N
v
2
m
g
L
T
b
A
(
k
s
i
b
c
t
t
t
b
a
cK.S. Vannice et al. / Va
ntibodies (MAbs) identiﬁed so far recognize epitopes in domain
II of the E protein (EDIII), which appear to be involved in binding
f DENV to cell receptors [23–31]. The conundrum of the human
ntibody response to DENV infection is that most antibodies are
peciﬁc for domain II of the E protein (EDII) [23] – which contains
 variety of serotype and ﬂavivirus cross-reactive epitopes – and
lso the protein’s molecular hinge located at the junction of EDI
nd EDII [32]. Additionally, accumulating experimental evidence
sing human MAbs derived from DENV-infected individuals has
dentiﬁed “conformational” epitopes that span non-linear regions
ithin or between the E-protein homodimers [33–37]. It has been
uggested that recognition of these conformational epitopes is
uman-speciﬁc, however it is likely that similar antibodies are
eveloped by other animal species (e.g., mice), but have yet to be
dentiﬁed due to the approaches used to screen murine MAbs. The
ontribution of the human antibody bias to EDII to ADE has not been
etermined. Because of its antigenic nature, EDIII is considered as
n immunologic target of particular relevance for dengue vaccine
evelopment. New vaccine strategies may  have to be developed
o enhance the human anti-EDIII response. Antibodies directed
gainst the C protein and against nonstructural proteins, such as
S1, have also been detected in DENV-infected individuals, but
heir role in dengue immunity or immunopathogenesis remains
nclear [11].
Dengue vaccine development has been hampered by the lack of
n adequate animal model for the disease [38]. Normal mice do not
isplay signiﬁcant viraemia or disease when infected with human
ENV isolates. Intracerebral challenge of mice with certain mouse-
dapted DENV strains produces a paralysis phenotype, and this
ntracerebral challenge model has been used to evaluate protective
fﬁcacy of vaccine candidates in mice. Furthermore, immunocom-
romised mouse models have been developed that show some of
he characteristics of human disease and can also be used as an
n vivo system for studying ADE [39–41]. However, concerns remain
bout whether the full spectrum of dengue immunity and disease
an be modelled in this immunocompromised setting. Humanized
ice that lack a murine antibody response but demonstrate some
ymptoms that re-capitulate human infection are also being inves-
igated [42,43]. NHPs are susceptible to infection by DENV and
evelop viraemia but do not show signiﬁcant clinical signs of infec-
ion. Studies to address protective efﬁcacy of vaccine candidates in
HPs therefore measure prevention or reduction of viraemia upon
iral challenge [38].
.2. Technological approaches to dengue vaccine development
The development of dengue vaccines has a long history, and has
ostly focused on live attenuated virus (LAV) vaccine technolo-
ies, also following the example of the successful development of
AV vaccines against Japanese encephalitis (JE) and yellow fever.
he LAVs have the capacity to replicate in the host, thereby resem-
ling natural infection, and inducing similar immune responses.
ttenuation has been achieved through serial passage of wild-type
wt) virus on nonhuman host cells, in particular using primary dog
idney (PDK) cells. Attenuated strains have classically been tested
eparately for safety and immunogenicity before being formulated
nto a tetravalent product. The ﬁrst such vaccine was developed
y Mahidol University, followed by other developers [44]. For all
andidates, the formulation into a tetravalent mixture while main-
aining a balanced immune response against all four strains proved
o be very difﬁcult and required very careful and empiric formula-
ion efforts [45,46]. Vaccine candidates have progressed to Phase 2
ut currently no such candidate is in active clinical development as
 standalone approach [47].
In the attempt to overcome immune interference between vac-
ine components when formulating tetravalent vaccines, and as a3 (2015) 7091–7099 7093
way to attenuate viruses in a more rational way, clonal vaccines
were developed using recombinant DNA technology. Attenuation
was achieved by rationally introducing mutations into the viral
genome, by chimerization with other ﬂaviviruses (Yellow fever
vaccine strain), and by using classically attenuated viral strains
as backbone [48]. These vaccine candidates are produced in con-
tinuous cell culture, in contrast to the classical vaccines that are
being produced in primary cells lines. The recombinant products
are also believed to be more genetically stable, minimizing the risk
of reversion to a more virulent phenotype. Most vaccine candidates
in advanced clinical development fall into this product category,
as well as several vaccines yet at preclinical stage of development
[49,50].
Overall, experience with live attenuated and live recombinant
candidate vaccines having advanced to clinical evaluation shows
that, once formulated into tetravalent vaccines, some level of inter-
ference between the virus strains occurs, leading to a dampened
immune response as compared to monovalent vaccine candidates.
Also, the ability to boost the immune response through repeat vac-
cination is limited [51].
More recent approaches to develop live vaccines also include
the development of virus vectored vaccines based mostly on
non-ﬂavivirus backbones. Prominent examples include adenovirus,
poxvirus, Venezuelan Equine Encephalitis (VEE) virus and measles
vaccine virus vectors [52–54]. Viral vectors, similar to other live
vaccines, have the propensity to induce synthesis of antigen within
cells, hereby triggering both humoral and cellular, including cyto-
toxic T cell responses. While humoral responses are considered
the most important for protective efﬁcacy, cellular responses
might assist in clearance of pathogen. Most viral vectors are non-
replicating, are very safe and have a track record of inducing broad
immune responses. An alternative strategy has been pursued in
developing a capsid-gene deleted West Nile virus that undergoes a
single round of replication in the host. In contrast, immunogenic-
ity of viral vector vaccines can be hampered by pre-existing vector
immunity, and maybe not or be only poorly boosted by homologous
vaccine [55].
A large array of non-living vaccine approaches are also under
development. Non-living vaccines have some theoretical advan-
tages over live vaccines, such as the inability to revert to more
virulence and better suitability for immunocompromised sub-
jects. It is also expected that interference between viral strains,
as observed in live tetravalent candidates, will not, or only to
a lesser degree, occur in this product category. Non-living vac-
cines tend to induce less broad, durable and vigorous immune
responses compared to LAV vaccines, however. Adjuvants or struc-
tural organization of antigen into virus-like particles (VLPs) can
help to increase immunogenicity, but may  increase the complex-
ity of vaccine development and require access to advanced, often
proprietary, platform technologies. In addition, adjuvants may
increase reactogenicity, and have occasionally raised safety con-
cerns. Finally, such vaccines typically require several doses for
primary immunization.
The simplest form of non-living vaccine is the puriﬁed, inactiv-
ated vaccine (PIV). Successfully developed as vaccines against JE
and tick-borne encephalitis, they have now reached early clinical
development for dengue. Vaccines may  need to be formulated with
adjuvants to achieve acceptable immunogenicity [56].
Recombinant subunit vaccines in contrast target speciﬁc epi-
topes considered important for protective immunity. Most dengue
subunit vaccines contain truncated versions of the E protein that
have deleted the transmembrane domain, or simply harbour the E
protein domain III. A variety of increasingly powerful expression
systems are now available of bacterial, yeast, insect or mammalian
origin, allowing economical production of antigen. An insect cell-
derived product has entered clinical evaluation [57]. Puriﬁcation of
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ntigen, in contrast, can be more demanding. Most subunit anti-
en is insufﬁciently immunogenic and requires adjuvant to elicit
cceptable levels of immunogenicity. An alternative to adjuvant use
s the display of antigen in an ordered, repetitive manner, similar
o the surface of virion structures. Several of such VLP candidates
re in development.
Other investigators have explored the development of DNA vac-
ines. If delivered into cells, plasmid DNA is transcribed into mRNA
hich is translated into protein that can be transported to the cell
urface as after viral infection, and antigen assembly in form of
LPs may  occur. While DNA vaccines have a number of theoretical
dvantages, they have not yet shown great potential in humans,
argely due to inefﬁcient cellular uptake of DNA. While this pro-
ess can be enhanced by certain adjuvants, intracellular targeting
f plasmid DNA into the nucleus represents another hurdle [58].
As all described vaccine technologies have their potential and
hortcomings, interest has been raised into combining vaccines in
eterologous-prime boost schedules, exploiting vaccines with opti-
al  priming potential and other with strong boosting capabilities.
. Dengue vaccine candidates in preclinical development
.1. Recombinant subunit vaccines
The Pedro Kourí Tropical Medicine Institute (IPK) and the Cen-
re for Genetic Engineering and Biotechnology (CIGB) in Cuba have
eveloped a domain III-capsid (DIII-C) vaccine, which is in advanced
reclinical studies. Two approaches have been combined to pro-
uce a tetravalent formulation, so far tested only in mice. In one,
he DENV EDIII protein is fused to the carrier protein p64k of
eisseria meningitidis for each of the four serotypes. The EDIII-
64k fusion protein is expressed in Escherichia coli.  DENV-1 and
ENV-2 monovalent candidates have also been evaluated in NHPs
59]. Monkeys were immunized subcutaneously with four doses
f the monovalent vaccine (50–100 g protein per dose, formu-
ated in Freund’s adjuvant). The monovalent vaccine candidates
ere found to be immunogenic and provided protection against
iral challenge [60,61]. The second approach uses a DENV EDIII-
apsid fusion protein (DIIIC-2) expressed in E. coli and mixed
n vitro with oligodeoxynucleotides to obtain particulated aggre-
ates (serotype 2) [62]. It was recently shown that the aggregated
ENV-2 EDIII-capsid fusion protein aggregated with a speciﬁc
ligodeoxynucleotide, selected for high cellular immune response,
nd adjuvanted in alum induced both humoral and cellular immune
esponses in NHPs and completely protected two of three animals
mmunized with four doses [63]. When these two approaches were
ombined into a tetravalent formulation and evaluated in mice, the
ntibody response to serotype 4 was low (GMT < 1:10) and survival
ost challenge ranged from 40% to approximately 70% for DENV-
, DEVN-2, and DENV-4 (DENV-3 virus challenge did not reduce
urvival for any animal) [64]. The tetravalent formulation of EDIII-
apsid fusion protein is currently under evaluation in NHPs. The
ifferent subunit vaccine candidates are also being studied in the
ontext of heterologous prime-boost strategies [65,66].
VaxInnate has updated their subunit vaccine candidate to now
nclude the ectodomain of the envelope (80E) antigen geneti-
ally fused to bacterial ﬂagellin, a TLR5 ligand from Salmonella
yphimurium ﬂagellin (STF2) [67], following suboptimal immuno-
enicity and partial protection with the EIII fusion vaccine in NHP
68]. This approach links adaptive and innate immunity and is
elieved to mimic  natural infection where antigen and TLR ligand
re contained in a single pathogen. Physical linkage of TLR ligand
o antigen has been shown to be more speciﬁc and efﬁcient than
o-administration. STF2 fusion proteins can be expressed and puri-
ed in baculovirus/insect cells. Four lead monovalent candidates3 (2015) 7091–7099
using 80E have been identiﬁed in mouse studies, and a NHP study
is scheduled for this year. The same platform has been used for
inﬂuenza vaccines in clinical development and was well-tolerated
and immunogenic [69,70].
A different approach to the development of a single tetrava-
lent subunit vaccine was  taken at the Taiwanese National Health
Research Institutes (NHRI). A consensus EDIII amino acid sequence
was derived by sequence analysis of different DENV-1–4 strains
to avoid immune interference between the serotypes, and the
consensus EDIII protein was  expressed in E. coli. The single tetrava-
lent vaccine candidate adjuvanted with alum induced neutralizing
antibody responses against all DENV serotypes in mice [71]. When
evaluated in NHPs on an immunization schedule of two  doses
over 8 weeks, 2/3 of the monkeys developed neutralizing anti-
body titres again DENV-2, but not against the other three serotypes
[72]. Aluminium adjuvant was  critical to generate these responses.
Additionally, NHRI has evaluated a recombinant lipidated EDIII,
both monovalent and the consensus EDIII [73,74] to improve the
immunogenicity without the need for adjuvant. In mice, neutral-
izing antibody titres were signiﬁcantly higher with a monovalent
dengue 4 lipidated EDIII than for the non-lipidated EDIII over 20
weeks post immunization and had signiﬁcantly reduced viraemia
when challenged with DEN-4 [75].
3.2. DNA vaccines
A tetravalent DNA vaccine candidate has been developed by the
U.S. Centres for Disease Control and Prevention (CDC). Transfec-
tion of the recombinant plasmid vectors into cultured cells has
been shown to result in secretion of prM/E containing VLPs, which
have an antigenic structure similar to DEN virions [76,77]. Immuno-
genicity of a tetravalent mixture of four monovalent DNA vaccines
has been evaluated in NHPs. The tetravalent vaccine was  found
to stimulate a balanced immunity that lasted for 10 months and
appeared to protect from viral challenge (J. Chang, personal com-
munication), though the ﬁnal results of the study have never been
published.
In a prototype DENV-1 DNA vaccine (D1ME100) Phase 1 clinical
trial in humans [78], a minority of participants developed anti-
dengue neutralizing antibody responses but IFN T cell responses
were frequently detected. As a result, the U.S. Naval Medical
Research Centre (NMRC) is pursuing an approach of adjuvanting the
tetravalent dengue DNA vaccine, which is composed of equal parts
of monovalent plasmid DNA vaccines encoding the PrM and E genes
[79–82], with the proprietary adjuvant Vaxfectin®. Vaxfectin® is a
cationic lipid:neutral lipid combination [83]. In a published study
in NHPs, animals were vaccinated on days 0, 28, and 84 with 3 mg
of Vaxfectin®-adjuvanted tetravalent DNA vaccine (TVDVVAX), and
then challenged approximately 6 months after the initial vacci-
nation with DENV-2 [84]. The addition of Vaxfectin® increased
anti-dengue neutralizing antibody responses against DEN-1, DENV-
3, and DENV-4 compared to DNA vaccine alone (TVDV). Antibody
responses developed more quickly (4/4 animals had detectable
neutralizing antibodies to all four serotypes 1 month after the ﬁrst
boost compared to 0/4 that received unadjuvanted vaccine). Peak
GMTs for TVDVVAX were 250 (S.E. ± 61.1), 271 (S.E. ± 26.8), 167
(S.E. ± 25.1), and 80.5 (S.E. ± 32.1) for DENV-1, DENV-2, DENV-3,
and DENV-4, respectively, with mean peak titres were statistically
signiﬁcantly higher with TVDVVAX for DENV-1, DENV-3, and DENV-
4 than TVDV alone. The addition of Vaxfectin® did not affect T cell
responses, which were detectable. Upon challenge, the mean dura-
tion of viraemia was  0.75 days for the TVDVVAX group, 2.0 days
in the TVDV group, and 3.3 days in the control group. A Phase 1
study of this tetravalent DNA vaccine formulated with Vaxfectin®
has recently been completed (NCT01502358). Work is ongoing to
improve immunogenicity with different routes of administration
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e.g., intradermal needle-free vaccine administration) and other
pproaches (e.g., prime-boost).
Progress with DNA vaccines has lagged behind other technolog-
cal approaches. The tetravalent DNA vaccine candidate developed
y Inovio Pharmaceuticals, which was comprised by the EDIII
omains of all four DENV serotypes separated by proteolytic cleav-
ge sites [85], no longer appears to be under active development.
nother tetravalent DNA vaccine candidate developed at Kobe Uni-
ersity, which is composed of a mixture of four plasmid vectors,
ach of which expresses the prM and E proteins (prM/E) of one
ENV serotype [86], is still under the antigen optimization stage
o yield high quality antibody and has not yet been tested in NHPs
E. Konishi, personal communication). FIOCRUZ also continues to
ursue DNA vaccines: a DNA vaccine encoding the NGC DENV-
 ectodomain (domains I, II, and III) fused to a signal sequence
rom the human tissue plasminogen activator, pE1D2 [87], is under
evelopment in combination with a chimeric yellow fever vaccine
see description with live attenuated vaccines below). The pcT-
ANS1 DNA vaccine, which contains the NS1 gene from DENV-2,
lso induced antibody response and protected 97% mice from chal-
enge with DENV-2 without neutralizing antibodies [88], while DNA
accines based on the NS3 protein elicited poor levels of antibody
nd conferred incomplete to no protection, particularly against
orbidity, post-DENV-2 challenge [89].
.3. VLP vaccines
VLP vaccine candidates have been developed by the Interna-
ional Centre for Genetic Engineering and Biotechnology (ICGEB)
nd are still under active development. In a ﬁrst approach, DENV
 was expressed as a fusion protein with Hepatitis B virus surface
ntigen (HBsAg) in Pichia pastoris [90]. HBsAg expressed in P. pas-
oris has been shown to assemble into highly immunogenic VLPs.
urthermore, high protein yields (up to 7 g HBsAg per litre culture
91]) make P. pastoris an attractive system for affordable produc-
ion of protein-based vaccines. While expression of EDIII alone does
ot result in VLP formation, it has been shown that one copy of
DIII-HBsAg and four copies of HBsAg optimally display EDIII on
he mosaic VLP surface [92]. The tetravalent formulation contains
ead-to-tail concatamer of EDIII from each serotype, and it has
een shown to elicit neutralizing antibodies to all four serotypes
n mice. The tetravalent formulation is currently under evaluation
n NHPs. An alternative approach, so far constrained to DENV-2 and
or which a fusion protein consisting of the E protein ectodomain
ectoE) and 30 amino residues of the prM protein was expressed in
. pastoris [93], is also under evaluation in NHP.
VLP vaccines from Cytos [94] (based on recombinant EDIII to
arrier VLPs derived from bacteriophage Q) and Kobe University
in which prM/E is expressed from a plasmid vector transfected
nto cell culture-based expression systems and secreted VLPs are
uriﬁed) [95] have not yet progressed to NHP studies.
.4. Virus-vectored vaccines
A virus-vectored vaccine candidate developed at the University
f North Carolina at Chapel Hill (UNC) and Global Vaccines is based
n expression of DENV antigens from a single-VEE virus vaccine
ector [53,96,97]. Packaging technologies based on helper RNAs
llow for the production of infectious single-cycle VEE virus par-
icles also referred to as virus replicon particles (VRPs). VEE VRPs
ave been shown to infect human dendritic cells and express high
evels of recombinant antigens, inducing both innate and adaptive
mmune responses in mice and NHPs. In a comparison of E85-VRP
85% C-terminally truncated protein) and prME-VRP, E85-VRP has
een selected for further development. Two doses of a tetravalent
85-VRP vaccine (108 IU of each serotype-VRP) given 6 weeks apart3 (2015) 7091–7099 7095
induced 100% seroconversion against all 4 serotypes, with no evi-
dence of interference. Animals were challenged 18 weeks after the
second vaccination with each serotype. Viraemia was  undetectable
after DENV-3 and DENV-4 challenges, and there was a signiﬁ-
cant reduction in viraemia duration after challenge with DENV-1
and DENV-2 [97]. Studies in weanling mice from dengue-naive or
dengue-immune dams demonstrated similar levels of neutralizing
antibodies while maternal antibodies were still detectable, sug-
gesting that the VRP vaccine may  be able to overcome interfering
maternal antibodies [96]. Tetravalent E85-VRP vaccination induced
similar antibody and T cell responses to monovalent vaccine, and
could be boosted [53].
A virus-vectored dengue vaccine candidate developed by
Themis Bioscience and Institut Pasteur is based on expression of
a single tetravalent DENV antigen construct from a live attenuated
measles virus vaccine vector (strain Schwarz) to produce MV-DEN
[98]. This vaccine vector technology allows for integration of large
antigen inserts and has been shown to induce strong neutralizing
antibodies and cellular immune responses even in the presence
of pre-existing immunity to measles virus. The dengue vaccine
candidate expresses a construct containing the EDIII domains of
DENV-1–4 as well as the DENV-1M protein ectodomain (ectoM).
Inclusion of ectoM in the vaccine construct was  found to provide
an adjuvant activity [99]. The single component tetravalent vac-
cine induced neutralizing antibodies against all DENV serotypes in
mice [98] and NHP (Ramsauer, personal communication). The same
platform expressing Chikungunya antigens was recently evaluated
in a Phase 1 clinical trial and found to be immunogenic against
Chikungunya, even in the presence of measles immunity, and with-
out safety concerns [100]. The GMP  manufacturing strategy for the
MV-CHIK vaccine can be applied to MV-DEN product. A Phase 1
clinical study for MV-DEN is under preparation.
The adenovirus-vectored chimeric EDIII fusion protein dengue
vaccine developed by ICGEB [52] is not currently in active devel-
opment, although it may  be reactivated as a prime-boost with
other candidates. The NMRC/GenPhar adenovirus-vectored candi-
date [101] has been discontinued. The University of Texas Medical
Branch (UTMB) single-cycle, capsid-gene deleted West Nile virus
vaccine vector [102,103] was licensed to a vaccine manufacturer
and has not been further developed (A. Barrett, personal commu-
nication).
3.5. Puriﬁed inactivated virus vaccines
A puriﬁed psoralen-inactivated DENV-1 vaccine candidate has
been developed by the NMRC [104]. A monovalent DENV-1 can-
didate adjuvanted in alum was  evaluated in NHPs using a three
dose schedule (intradermal injection, biweekly intervals). Immu-
nized monkeys showed a DENV-1 neutralizing antibody response
and reduced duration of viraemia upon viral challenge on day 132,
suggesting that the vaccine candidate provides partial protection
in NHPs. It has been recently shown that the binding capacity of a
panel of monoclonal antibodies was  reduced 30–60% when DENV-2
was inactivated by formaldehyde and iodonaphthyl azide com-
pared to psoralen [105]. Work is ongoing to establish the superior
immunogenicity of psoralen inactivation compared to formalin.
PIV vaccine candidates developed by Walter Reed Army Institute
of Research (WRAIR) and licensed to GSK are being co-developed
along with the Oswaldo Cruz Foundation (FIOCRUZ) [106]. Differ-
ent approaches for virus inactivation and puriﬁcation and various
adjuvant systems are currently under evaluation; GSK and WRAIR
have a candidate using the GSK proprietary adjuvant system (AS01,
AS03) or alum under evaluation in clinical trials after testing in
NHPs [56]. In the collaboration with FIOCRUZ, other virus collec-
tions are being used and are still under preclinical development
with studies in NHPs.
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A new approach under development by Global Vaccines is based
n an adjuvanted inactivated DENV (iDV) vaccine using adjuvants
VI3000 and GVI3A, based on VEE replicon particles. These adju-
ant genomes lack VEE structural protein genes or heterologous
ntigen genes. Studies of monovalent and tetravalent iDV vac-
ines with adjuvant have been completed in mice and NHP and
emonstrated enhanced neutralizing antibody titres, detectable T
ell responses, and protective efﬁcacy (White, personal communi-
ation).
.6. Live attenuated virus vaccines
Another live attenuated vaccine candidate has been developed
n a collaboration between Chiang Mai  University, Mahidol Univer-
ity, and the Thai National Science and Technology Development
gency (NSTDA). DEN/DEN chimeric viruses were constructed
hich contain the prM/E coding region of recent dengue clinical
solates in the genetic background of attenuated DENV-2, includ-
ng a pr-M cleavage enhancing mutation. It has been shown in
HP’s that one dose better protects against viraemia when chal-
enged with DENV-1 or DENV-2 compared to the chimeric virus
ithout the pr-M cleavage enhancing mutation [49]. The monova-
ent DENV-1 prM + E-chimeric dengue vaccine is being planned for
MP  manufacturing and toxicology studies in Thailand. The other
onovalent chimeric constructs are being evaluated currently in
HPs.
Arbovax has developed a live attenuated tetravalent vaccine
sing host range (HR) mutations to select for viruses that replicate
ell in insect cells but not in mammalian cells. Vaccine viruses
or each serotype were developed by truncating transmembrane
omain 1 of the E protein. A tetravalent formulation (called HR-
et, composed of 106 PFU/mL of each vaccine strain) was tested
or immunogenicity in NHPs [107]. All animals seroconverted to
ll four strains by 62 days post vaccination. Peak GMTs were 538,
69, 252, and 742 against DENV-1, DENV-2, DENV-3, and DENV-4,
espectively. HR-Tet has been approved by the FDA at the pre-IND
tage for further development. It is anticipated that clinical studies
ill start in early 2016.
The Beijing Institute of Microbiology and Epidemiology,
ogether with the Chengdu Institute of Biological Products and
thers, has developed a chimeric DENV based on the JE live vac-
ine strain SA 14-14-2 as a backbone (ChinDENV). ChinDENV
etains the prM signal peptide of SA 14-14-2 and the last three
mino acids at the terminus of the E protein [108]. A monova-
ent DENV-2 was evaluated in mice and NHP [109]. ChinDENV
as found to be less neurovirulent than either parental virus in
ice when 2-day old mice were administered ChinDENV by the
ntracerebral route. Dengue-speciﬁc neutralizing antibodies were
ose-dependent, although peak titres at day 42 were lower in JEV
A 14-14-2 primed mice. Mice vaccinated with ChinDENV were
rotected against lethal JEV challenge. In NHPs, peak GMTs were
eached on day 20 post-vaccination, at 184 and 204 in the 1 × 104
nd 1 × 105 PFU groups. All animals receiving these doses were pro-
ected from viraemia post challenge with DENV-2 virus.
The Agency for Science, Technology and Research in Singapore
ogether with the Novartis Institute for Tropical Diseases and oth-
rs have developed a live attenuated dengue vaccine that lacks
′-O-methyltransferase activity. This mutation prohibits the virus
rom shielding viral RNA from host innate immune factors, thereby
riggering an interferon response in the infected cell. The mutant
iruses replicate to high titres in cell culture but they are highly
ttenuated in mice and NHPs. A single dose of monovalent vaccine
rotected NHP from viraemia when challenged with DENV-2 [50].
 1/2 bivalent vaccine in mice did not diminish antibody responses
ompared to monovalent vaccines, suggesting a lack of interfer-
nce, and were mostly protected against challenge with lethal3 (2015) 7091–7099
doses of either DENV-1 or DENV-2 virus. Aedes aegypti mosquitoes
were fed blood containing wild type virus or vaccine; while even
at low doses some mosquitoes were always infected, the mutant
virus did not infect any mosquitoes.
3.7. Heterologous prime-boost approaches
In addition to those efforts described above, a few other heterol-
ogous prime-boost approaches are under evaluation. A prime-boost
approach developed by the NMRC using a combination of a DNA
vaccine candidate and a virus-vectored vaccine candidate was
evaluated and later discontinued [110]. Other heterologous prime-
boost approaches developed by the NMRC and the WRAIR using
non-replicating vaccines for priming, followed by boosting with
a LAV vaccine candidate are still being investigated [111]. Two
non-replicating “priming” vaccines are being evaluated: a tetrava-
lent DNA vaccine composed of plasmid vectors expressing DENV
prM/E [78] and a tetravalent PIV vaccine consisting of formalin-
inactivated DENV adjuvanted with alum [106]. The tetravalent LAV
vaccine candidate, which was developed by GSK and WRAIR using
serial passage of clinical DENV isolates in PDK cells, has reached
Phase 2 clinical trials [112]. To determine which of the two non-
replicating vaccine candidates was more effective for priming, a
DNA–DNA–LAV vaccination schedule (at 30, 0 and 60 days) was
compared to a PIV–LAV vaccination schedule (at 0 and 60 days)
in NHPs. Both regimens were found to elicit neutralizing antibody
responses. However, priming with the DNA vaccine provided only
partial protection against viral challenge 6 months after the last
dose, as evidenced by the observation of breakthrough viraemia.
Work continues to optimize the DNA priming dose. By contrast,
priming with one dose of PIV vaccine followed by a LAV vaccine
booster dose 2 months later resulted in complete protection against
challenge with any of the four DENV serotypes [111]. Phase 1
human clinical trials using the PIV–LAV vaccination strategy has
recently been initiated (NCT02239614).
A live attenuated dengue vaccine candidate developed by
FIOCRUZ uses the live attenuated yellow fever vaccine 17DD sub-
strain as a genetic backbone. Chimeric YF 17D/DEN viruses were
constructed by replacing the Yellow fever virus prM/E genes with
those of DENV strains from Latin America [113]. Neutralizing anti-
body responses and protection against viral challenge have been
shown [114–116]. Combinations of prime/boost and simultaneous
vaccination with a DNA vaccine (pE1D2), described brieﬂy in Sec-
tion 3.2, have been studied in mice with high levels of neutralizing
antibodies, generated using these different approaches [117]. Vac-
cination with pE1D2 DNA and YF17D-D2 monovalent vaccines
together improved neutralizing antibody production compared to
the same vaccines administered isolated. NHP studies are planned
to conﬁrm the results obtained in mice.
While heterologous prime-boost strategies may  offer advan-
tages over other vaccination approaches, recent investigations with
West Nile virus vaccine candidates suggest that the order of anti-
gens used in a heterologous prime-boost approach was important
in terms of the speciﬁcity and magnitude of the immune response
[118]. Similar results can be expected for dengue vaccines. Recent
consultations at WHO  on heterologous prime-boost strategies of
vectored vaccines did not reveal particular regulatory hurdles, but
cost of goods and complexities around vaccine use would likely
be less favourable than for homologous vaccination approaches
[119,120].4. Conclusions
Efforts to develop dengue vaccines have been ongoing for many
years, but recent advances in vaccine science have greatly increased
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he technological options for dengue vaccine development. In par-
llel, molecular biology and systems biology permit more speciﬁc
nalysis of vaccine-induced immunogenicity and safety. However,
ossibly the most intriguing ﬁnding in relation to dengue vac-
ines over the past years comes from the ﬁrst in class vaccine
fﬁcacy trial conducted with a yellow fever/dengue chimeric vac-
ine candidate. The observed mismatch between protective efﬁcacy
nd neutralizing titres demonstrates our limited understanding of
rotective immunity in dengue and the shortcomings of our diag-
ostic assays to measure vaccine induced immunity [13]. While the
accine community awaits more detailed analysis of the dengue
accine efﬁcacy trials, interest has been renewed in evaluation of
arly stage candidates, both in NHPs and human challenge studies
121,122]. Dengue vaccine development remains an empiric pro-
ess that needs to be informed by the most relevant experimental
ata.
The preclinical dengue vaccine pipeline covers a broad range
f approaches, both in relation to antigen as well as in relation to
elivery and presentation. This diversity in approaches is highly
omplementary to the candidate vaccines currently in advanced
linical development, which are all live tetravalent products. This
iversity is a major asset in light of the partial efﬁcacy shown
y the initial vaccine evaluated for clinical efﬁcacy. Second gen-
ration vaccines may  improve upon ﬁrst generation vaccines in
elation to overall and strain-speciﬁc vaccine efﬁcacy, in particular
n immunologically naïve subjects, and more favourable immuniza-
ion schedules.
Carefully designed studies in non-human primates, with all the
imitations of these models, should allow prioritization of pre-
linical candidates for human subject trials [123]. The clinical
evelopment of second generation vaccines would be greatly facil-
tated if we had established correlates of protection. Recent and
uture efﬁcacy trials have the potential to further our understand-
ng of correlates, even though they may  differ between vaccine
ypes and strains. The much welcomed progress in the vaccine
ipeline should not let us lose sight of furthering our understanding
f basic biological and immunological aspects of dengue disease.
isclaimer
Kirsten Vannice and Joachim Hombach are staff members of the
orld Health Organization. The authors alone are responsible for
he views expressed in this publication and they do not necessarily
epresent the decisions or policies of the World Health Organiza-
ion.
onﬂict of interest statement
None.
cknowledgements
We  would like to thank the following individuals for providing
pdated information on vaccine candidates: Alan Barrett (UTMB)
aura White (Global Vaccines), Malcolm Thomas (Arbovax), Kevin
orter (U.S. Navy Medical Research Centre), Eiji Konishi (Kobe
niversity), Nopporn Sittisombut (Chiang Mai  University), Katrin
amsauer (Themis Bio), Ge Liu (VaxInnate), Maria Guzman (Pedro
ouri Institute for Tropical Medicine), Marcos da Silver Freire and
da Alves (Fiocruz), and Navin Khanna (ICGEB).eferences
[1] World Health Organization. Global strategy for dengue prevention and con-
trol, 2012–2020; 2012. Geneva, Switzerland.3 (2015) 7091–7099 7097
[2] Bhatt S, Gething PW,  Brady OJ, Messina JP, Farlow AW,  Moyes CL, et al. The
global distribution and burden of dengue. Nature 2013;496(7446):504–7.
[3] Achee NL, Gould F, Perkins TA, Reiner Jr RC, Morrison AC, Ritchie SA, et al. A
critical assessment of vector control for dengue prevention. PLoS Negl Trop
Dis  2015;9(5):e0003655.
[4] Capeding MR,  Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua
MN,  et al. Clinical efﬁcacy and safety of a novel tetravalent dengue vaccine in
healthy children in Asia: a phase 3, randomised, observer-masked, placebo-
controlled trial. Lancet 2014;384(9951):1358–65.
[5] Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM,  Cunha R, Deseda C, et al.
Efﬁcacy of a tetravalent dengue vaccine in children in Latin America. N Engl J
Med  2015;372(2):113–23.
[6] Hadinegoro SR, Arredondo-Garcia JL, Capeding MR,  Deseda C, Chotpitaya-
sunondh T, Dietze R, et al. Efﬁcacy and long-term safety of a dengue vaccine
in  regions of endemic disease. N Engl J Med  2015;373(13):1195–206.
[7] Simmons CP. A candidate dengue vaccine walks a tightrope. N Engl J Med
2015;373(13):1263–4.
[8] Pasteur S. New England Journal of Medicine publishes new analyses
conﬁrming that Sanoﬁ Pasteur’s vaccine candidate safely protects pre-
adolescents to adults against dengue; 2015. Lyon, France.
[9] Schmitz J, Roehrig J, Barrett A, Hombach J. Next generation dengue
vaccines: a review of candidates in preclinical development. Vaccine
2011;29(42):7276–84.
[10] Messina JP, Brady OJ, Scott TW,  Zou C, Pigott DM,  Duda KA, et al. Global
spread of dengue virus types: mapping the 70 year history. Trends Microbiol
2014;22(3):138–46.
[11] Murphy BR, Whitehead SS. Immune response to dengue virus and prospects
for  a vaccine. Annu Rev Immunol 2011;29:587–619.
[12] Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P,
Suvannadabba S, et al. Protective efﬁcacy of the recombinant, live-attenuated,
CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, con-
trolled phase 2b trial. Lancet 2012;380(9853):1559–67.
[13] Sirivichayakul C, Sabchareon A, Limkittikul K, Yoksan S. Plaque reduction
neutralization antibody test does not accurately predict protection against
dengue infection in Ratchaburi cohort, Thailand. Virol J 2014;11:48.
[14] Mukherjee S, Dowd KA, Manhart CJ, Ledgerwood JE, Durbin AP, Whitehead
SS, et al. Mechanism and signiﬁcance of cell type-dependent neutralization
of  ﬂaviviruses. J Virol 2014;88(13):7210–20.
[15] Hombach J, Cardosa MJ,  Sabchareon A, Vaughn DW,  Barrett AD. Scientiﬁc
consultation on immunological correlates of protection induced by dengue
vaccines report from a meeting held at the World Health Organization 17–18
November 2005. Vaccine 2007;25(21):4130–9.
[16] Halstead SB. Neutralization and antibody-dependent enhancement of dengue
viruses. Adv Virus Res 2003;60:421–67.
[17] Halstead SB. Antibodies determine virulence in dengue. Ann N Y Acad Sci
2009;1171(Suppl. 1):E48–56.
[18] Guzman MG,  Harris E. Dengue. Lancet 2015;385(9966):453–65.
[19] Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. Structural insights into
the mechanisms of antibody-mediated neutralization of ﬂavivirus infec-
tion: implications for vaccine development. Cell Host Microbe 2008;4(3):
229–38.
[20] Dowd KA, Pierson TC. Antibody-mediated neutralization of ﬂaviviruses: a
reductionist view. Virology 2011;411(2):306–15.
[21] Junjhon J, Edwards TJ, Utaipat U, Bowman VD, Holdaway HA, Zhang W,  et al.
Inﬂuence of pr-M cleavage on the heterogeneity of extracellular dengue virus
particles. J Virol 2010;84(16):8353–8.
[22] Perera R, Kuhn RJ. Structural proteomics of dengue virus. Curr Opin Microbiol
2008;11(4):369–77.
[23] Beltramello M,  Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT,
et  al. The human immune response to dengue virus is dominated by highly
cross-reactive antibodies endowed with neutralizing and enhancing activity.
Cell Host Microbe 2010;8(3):271–83.
[24] Crill WD,  Roehrig JT. Monoclonal antibodies that bind to domain III of dengue
virus E glycoprotein are the most efﬁcient blockers of virus adsorption to Vero
cells. J Virol 2001;75(16):7769–73.
[25] Roehrig JT. Antigenic structure of ﬂavivirus proteins. Adv Virus Res
2003;59:141–75.
[26] Brien JD, Austin SK, Sukupolvi-Petty S, O’Brien KM,  Johnson S, Fremont DH,
et al. Genotype-speciﬁc neutralization and protection by antibodies against
dengue virus type 3. J Virol 2010;84(20):10630–43.
[27] Dejnirattisai W,  Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S,
Limpitikul W,  et al. Cross-reacting antibodies enhance dengue virus infection
in  humans. Science 2010;328(5979):745–8.
[28] Rodenhuis-Zybert IA, van der Schaar HM,  da Silva Voorham JM,  van der
Ende-Metselaar H, Lei HY, Wilschut J, et al. Immature dengue virus: a veiled
pathogen? PLoS Pathog 2010;6(1):e1000718.
[29] Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA,  Kim T,
et al. The development of therapeutic antibodies that neutralize homol-
ogous and heterologous genotypes of dengue virus type 1. PLoS Pathog
2010;6(4):e1000823.
[30] Sukupolvi-Petty S, Austin SK, Engle M,  Brien JD, Dowd KA, Williams KL, et al.
Structure and function analysis of therapeutic monoclonal antibodies against
dengue virus type 2. J Virol 2010;84(18):9227–39.
[31] Wahala WM,  Donaldson EF, de Alwis R, Accavitti-Loper MA,  Baric RS, de Silva
AM.  Natural strain variation and antibody neutralization of dengue serotype
3  viruses. PLoS Pathog 2010;6(3):e1000821.
7 ccine 3098 K.S. Vannice et al. / Va
[32] Widman DG, Baric RS. Dengue virus envelope protein domain I/II hinge: a key
target for dengue virus vaccine design? Expert Rev Vaccines 2015;14(1):5–8.
[33] de Alwis R, Smith SA, Olivarez NP, Messer WB,  Huynh JP, Wahala WM,  et al.
Identiﬁcation of human neutralizing antibodies that bind to complex epitopes
on  dengue virions. Proc Natl Acad Sci U S A 2012;109(19):7439–44.
[34] Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM,  Crowe Jr JE. Isolation of
dengue virus-speciﬁc memory B cells with live virus antigen from human
subjects following natural infection reveals the presence of diverse novel
functional groups of antibody clones. J Virol 2014;88(21):12233–41.
[35] Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, Duquerroy S, Vaney MC,
Kikuti CM,  et al. Recognition determinants of broadly neutralizing human
antibodies against dengue viruses. Nature 2015;520(7545):109–13.
[36] Fibriansah G, Tan JL, Smith SA, de Alwis R, Ng TS, Kostyuchenko VA, et al. A
highly potent human antibody neutralizes dengue virus serotype 3 by binding
across three surface proteins. Nat Commun 2015;6:6341.
[37] Dejnirattisai W,  Wongwiwat W,  Supasa S, Zhang X, Dai X, Rouvinski A, et al.
A  new class of highly potent, broadly neutralizing antibodies isolated from
viremic patients infected with dengue virus. Nat Immunol 2015;16(2):170–7.
[38] Cassetti MC,  Durbin A, Harris E, Rico-Hesse R, Roehrig J, Rothman A,
et  al. Report of an NIAID workshop on dengue animal models. Vaccine
2010;28(26):4229–34.
[39] Williams KL, Zompi S, Beatty PR, Harris E. A mouse model for studying dengue
virus pathogenesis and immune response. Ann N Y Acad Sci 2009;1171(Suppl
1):E12–23.
[40] Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, et al. Lethal
antibody enhancement of dengue disease in mice is prevented by Fc modiﬁ-
cation. PLoS Pathog 2010;6(2):e1000790.
[41] Zellweger RM,  Prestwood TR, Shresta S. Enhanced infection of liver sinu-
soidal endothelial cells in a mouse model of antibody-induced severe dengue
disease. Cell Host Microbe 2010;7(2):128–39.
[42] Kuruvilla JG, Troyer RM, Devi S, Akkina R. Dengue virus infection and immune
response in humanized RAG2(−/−)gamma(c)(−/−) (RAG-hu) mice. Virology
2007;369(1):143–52.
[43] Mota J, Rico-Hesse R. Humanized mice show clinical signs of dengue fever
according to infecting virus genotype. J Virol 2009;83(17):8638–45.
[44] Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vac-
cine 2000;18(Suppl. 2):44–7.
[45] Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, et al.
Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vac-
cine. Am J Trop Med  Hyg 2003;69(Suppl. 6):48–60.
[46] Guy B, Barban V, Mantel N, Aguirre M,  Gulia S, Pontvianne J, et al. Evaluation
of interferences between dengue vaccine serotypes in a monkey model. Am J
Trop Med  Hyg 2009;80(2):302–11.
[47] Watanaveeradej V, Gibbons RV, Simasathien S, Nisalak A, Jarman RG, Kerd-
panich A, et al. Safety and immunogenicity of a rederived, live-attenuated
dengue virus vaccine in healthy adults living in Thailand: a randomized trial.
Am J Trop Med  Hyg 2014;91(1):119–28.
[48] Lin L, Thomas SJ. Current dengue vaccine status. Curr Trop Med  Rep
2014;1:6–12.
[49] Keelapang P, Nitatpattana N, Suphatrakul A, Punyahathaikul S, Sriburi R, Pul-
manausahakul R, et al. Generation and preclinical evaluation of a DENV-1/2
prM + E chimeric live attenuated vaccine candidate with enhanced prM cleav-
age. Vaccine 2013;31(44):5134–40.
[50] Zust R, Dong H, Li XF, Chang DC, Zhang B, Balakrishnan T, et al. Rational
design of a live attenuated dengue vaccine: 2′-o-methyltransferase mutants
are highly attenuated and immunogenic in mice and macaques. PLoS Pathog
2013;9(8):e1003521.
[51] Dayan GH, Garbes P, Noriega F, Izoton de Sadovsky AD, Rodrigues PM,  Giu-
berti C, et al. Immunogenicity and safety of a recombinant tetravalent dengue
vaccine in children and adolescents ages 9–16 years in Brazil. Am J Trop Med
Hyg  2013;89(6):1058–65.
[52] Khanam S, Pilankatta R, Khanna N, Swaminathan S. An adenovirus type 5
(AdV5) vector encoding an envelope domain III-based tetravalent antigen
elicits immune responses against all four dengue viruses in the presence of
prior AdV5 immunity. Vaccine 2009;27(43):6011–21.
[53] Khalil SM,  Tonkin DR, Mattocks MD,  Snead AT, Johnston RE, White LJ. A
tetravalent alphavirus-vector based dengue vaccine provides effective immu-
nity in an early life mouse model. Vaccine 2014;32(32):4068–74.
[54] Brandler S, Rufﬁe C, Combredet C, Brault JB, Najburg V, Prevost MC,  et al. A
recombinant measles vaccine expressing chikungunya virus-like particles is
strongly immunogenic and protects mice from lethal challenge with chikun-
gunya virus. Vaccine 2013;31(36):3718–25.
[55] Liu MA. Immunologic basis of vaccine vectors. Immunity 2010;33(4):504–15.
[56] Fernandez S, Thomas SJ, De La Barrera R, Im-Erbsin R, Jarman RG, Baras B, et al.
An adjuvanted, tetravalent dengue virus puriﬁed inactivated vaccine candi-
date induces long-lasting and protective antibody responses against dengue
challenge in rhesus macaques. Am J Trop Med  Hyg 2015;92(4):698–708.
[57] Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH. The development
of  recombinant subunit envelope-based vaccines to protect against dengue
virus induced disease. Vaccine 2011;29(42):7267–75.
[58] Ulmer JB, Mason PW,  Geall A, Mandl CW.  RNA-based vaccines. Vaccine
2012;30(30):4414–8.
[59] Valdes I, Hermida L, Martin J, Menendez T, Gil L, Lazo L, et al. Immunologi-
cal evaluation in nonhuman primates of formulations based on the chimeric
protein P64k-domain III of dengue 2 and two  components of Neisseria menin-
gitidis.  Vaccine 2009;27(7):995–1001.3 (2015) 7091–7099
[60] Hermida L, Bernardo L, Martin J, Alvarez M,  Prado I, Lopez C, et al. A recom-
binant fusion protein containing the domain III of the dengue-2 envelope
protein is immunogenic and protective in nonhuman primates. Vaccine
2006;24(16):3165–71.
[61] Bernardo L, Izquierdo A, Alvarez M,  Rosario D, Prado I, Lopez C, et al. Immuno-
genicity and protective efﬁcacy of a recombinant fusion protein containing
the domain III of the dengue 1 envelope protein in non-human primates.
Antivir Res 2008;80(2):194–9.
[62] Suzarte E, Marcos E, Gil L, Valdes I, Lazo L, Ramos Y, et al. Generation and
characterization of potential dengue vaccine candidates based on domain III
of the envelope protein and the capsid protein of the four serotypes of dengue
virus. Arch Virol 2014;159(7):1629–40.
[63] Gil L, Marcos E, Izquierdo A, Lazo L, Valdes I, Ambala P, et al. The pro-
tein DIIIC-2, aggregated with a speciﬁc oligodeoxynucleotide and adjuvanted
in  alum, protects mice and monkeys against DENV-2. Immunol Cell Biol
2015;93(1):57–66.
[64] Izquierdo A, Garcia A, Lazo L, Gil L, Marcos E, Alvarez M,  et al. A tetrava-
lent dengue vaccine containing a mix  of domain III-P64k and domain
III-capsid proteins induces a protective response in mice. Arch Virol
2014;159(10):2597–604.
[65] Valdes I, Hermida L, Gil L, Lazo L, Castro J, Martin J, et al. Heterologous prime-
boost strategy in non-human primates combining the infective dengue virus
and a recombinant protein in a formulation suitable for human use. Int J Infect
Dis  2010;14(5):e377–83.
[66] Valdes I, Gil L, Romero Y, Castro J, Puente P, Lazo L, et al. The chimeric protein
domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neu-
tralizing antibodies generated in monkeys upon infection with DEN-2. Clin
Vaccine Immunol 2011;18(3):455–9.
[67] McDonald WF,  Huleatt JW,  Foellmer HG, Hewitt D, Tang J, Desai P, et al. A West
Nile virus recombinant protein vaccine that coactivates innate and adaptive
immunity. J Infect Dis 2007;195(11):1607–17.
[68] Liu G, Song L, Beasley DW,  Putnak R, Parent J, Misczak J, et al. Immuno-
genicity and efﬁcacy of ﬂagellin-envelope fusion dengue vaccines in mice
and monkeys. Clin Vaccine Immunol 2015;22(5):516–25.
[69] Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, Fitzgerald T, et al. Safety and
immunogenicity of a recombinant hemagglutinin inﬂuenza-ﬂagellin fusion
vaccine (VAX125) in healthy young adults. Vaccine 2010;28(52):8268–74.
[70] Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, et al. Induction
of a potent immune response in the elderly using the TLR-5 agonist, ﬂag-
ellin, with a recombinant hemagglutinin inﬂuenza-ﬂagellin fusion vaccine
(VAX125, STF2.HA1 SI). Vaccine 2011;29(31):4897–902.
[71] Leng CH, Liu SJ, Tsai JP, Li YS, Chen MY,  Liu HH, et al. A novel dengue vaccine
candidate that induces cross-neutralizing antibodies and memory immunity.
Microbes Infect 2009;11(2):288–95.
[72] Chen HW,  Liu SJ, Li YS, Liu HH, Tsai JP, Chiang CY, et al. A consensus
envelope protein domain III can induce neutralizing antibody responses
against serotype 2 of dengue virus in non-human primates. Arch Virol
2013;158(7):1523–31.
[73] Chiang CY, Huang MH,  Pan CH, Hsieh CH, Chen MY,  Liu HH, et al. Induction
of  robust immunity by the emulsiﬁcation of recombinant lipidated dengue-1
envelope protein domain III. Microbes Infect 2013;15(10-11):719–28.
[74] Chiang CY, Liu SJ, Tsai JP, Li YS, Chen MY, Liu HH,  et al. A novel single-
dose dengue subunit vaccine induces memory immune responses. PLoS ONE
2011;6(8):e23319.
[75] Chiang CY, Hsieh CH, Chen MY,  Tsai JP, Liu HH, Liu SJ, et al. Recombinant
lipidated dengue-4 envelope protein domain III elicits protective immunity.
Vaccine 2014;32(12):1346–53.
[76] Chang GJ, Hunt AR, Holmes DA, Springﬁeld T, Chiueh TS, Roehrig JT, et al.
Enhancing biosynthesis and secretion of premembrane and envelope proteins
by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis
virus. Virology 2003;306(1):170–80.
[77] Purdy DE, Chang GJ. Secretion of noninfectious dengue virus-like particles
and identiﬁcation of amino acids in the stem region involved in intracellular
retention of envelope protein. Virology 2005;333(2):239–50.
[78] Beckett CG, Tjaden J, Burgess T, Danko JR, Tamminga C, Simmons M,  et al.
Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial.
Vaccine 2011;29(5):960–8.
[79] Raviprakash K, Porter KR, Kochel TJ, Ewing D, Simmons M,  Phillips I, et al.
Dengue virus type 1 DNA vaccine induces protective immune responses in
rhesus macaques. J Gen Virol 2000;81(Pt 7):1659–67.
[80] Raviprakash K, Marques E, Ewing D, Lu Y, Phillips I, Porter KR, et al. Synergis-
tic  neutralizing antibody response to a dengue virus type 2 DNA vaccine by
incorporation of lysosome-associated membrane protein sequences and use
of  plasmid expressing GM-CSF. Virology 2001;290(1):74–82.
[81] Blair PJ, Kochel TJ, Raviprakash K, Guevara C, Salazar M,  Wu SJ, et al. Evaluation
of  immunity and protective efﬁcacy of a dengue-3 pre-membrane and enve-
lope DNA vaccine in Aotus nancymae monkeys. Vaccine 2006;24(9):1427–32.
[82] Lu Y, Raviprakash K, Leao IC, Chikhlikar PR, Ewing D, Anwar A, et al. Dengue
2  PreM-E/LAMP chimera targeted to the MHC  class II compartment elicits
long-lasting neutralizing antibodies. Vaccine 2003;21(17–18):2178–89.
[83] Sullivan SM,  Doukas J, Hartikka J, Smith L, Rolland A. Vaxfectin: a versatile
adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin Drug
Deliv 2010;7(12):1433–46.
[84] Porter KR, Ewing D, Chen L, Wu SJ, Hayes CG, Ferrari M,  et al. Immunogenicity
and protective efﬁcacy of a vaxfectin-adjuvanted tetravalent dengue DNA
vaccine. Vaccine 2012;30(2):336–41.
ccine 3
[
[
[
[K.S. Vannice et al. / Va
[85] Ramanathan MP,  Kuo YC, Selling BH, Li Q, Sardesai NY, Kim JJ, et al. Develop-
ment of a novel DNA SynCon tetravalent dengue vaccine that elicits immune
responses against four serotypes. Vaccine 2009;27(46):6444–53.
[86] Konishi E, Kosugi S, Imoto J. Dengue tetravalent DNA vaccine inducing neutral-
izing antibody and anamnestic responses to four serotypes in mice. Vaccine
2006;24(12):2200–7.
[87] Azevedo AS, Yamamura AM,  Freire MS,  Trindade GF, Bonaldo M, Galler R, et al.
DNA vaccines against dengue virus type 2 based on truncate envelope protein
or  its domain III. PLoS ONE 2011;6(7):e20528.
[88] Costa SM,  Azevedo AS, Paes MV,  Sarges FS, Freire MS,  Alves AM. DNA vac-
cines against dengue virus based on the ns1 gene: the inﬂuence of different
signal sequences on the protein expression and its correlation to the immune
response elicited in mice. Virology 2007;358(2):413–23.
[89] Costa SM,  Yorio AP, Goncalves AJ, Vidale MM,  Costa EC, Mohana-Borges R,
et al. Induction of a protective response in mice by the dengue virus NS3
protein using DNA vaccines. PLoS ONE 2011;6(10):e25685.
[90] Bisht H, Chugh DA, Raje M,  Swaminathan SS, Khanna N. Recombinant
dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein
expressed in Pichia pastoris can function as a bivalent immunogen. J Bio-
technol 2002;99(2):97–110.
[91] Gurramkonda C, Adnan A, Gabel T, Lunsdorf H, Ross A, Nemani SK, et al.
Simple high-cell density fed-batch technique for high-level recombinant pro-
tein  production with Pichia pastoris: application to intracellular production
of  Hepatitis B surface antigen. Microb Cell Fact 2009;8:13.
[92] Khetarpal N, Poddar A, Nemani SK, Dhar N, Patil A, Negi P, et al. Dengue-
speciﬁc subviral nanoparticles: design, creation and characterization. J
Nanobiotechnol 2013;11:15.
[93] Mani S, Tripathi L, Raut R, Tyagi P, Arora U, Barman T, et al. Pichia
pastoris-expressed dengue 2 envelope forms virus-like particles without pre-
membrane protein and induces high titer neutralizing antibodies. PLoS ONE
2013;8(5):e64595.
[94] Spohn G, Jennings GT, Martina BE, Keller I, Beck M,  Pumpens P, et al. A VLP-
based vaccine targeting domain III of the West Nile virus E protein protects
from lethal infection in mice. Virol J 2010;7:146.
[95] Kuwahara M, Konishi E. Evaluation of extracellular subviral particles of
dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera
frugiperda cells for use as vaccine and diagnostic antigens. Clin Vaccine
Immunol 2010;17(10):1560–6.
[96] White LJ, Parsons MM,  Whitmore AC, Williams BM,  de Silva A, Johnston RE.
An  immunogenic and protective alphavirus replicon particle-based dengue
vaccine overcomes maternal antibody interference in weanling mice. J Virol
2007;81(19):10329–39.
[97] White LJ, Sariol CA, Mattocks MD,  Wahala MPBW,  Yingsiwaphat V, Collier ML,
et  al. An alphavirus vector-based tetravalent dengue vaccine induces a rapid
and protective immune response in macaques that differs qualitatively from
immunity induced by live virus infection. J Virol 2013;87(6):3409–24.
[98] Brandler S, Rufﬁe C, Najburg V, Frenkiel MP,  Bedouelle H, Despres P,
et  al. Pediatric measles vaccine expressing a dengue tetravalent anti-
gen elicits neutralizing antibodies against all four dengue viruses. Vaccine
2010;28(41):6730–9.
[99] Brandler S, Lucas-Hourani M,  Moris A, Frenkiel MP,  Combredet C, Fevrier M,
et  al. Pediatric measles vaccine expressing a dengue antigen induces durable
serotype-speciﬁc neutralizing antibodies to dengue virus. PLoS Negl Trop Dis
2007;1(3):e96.
100] Ramsauer K, Schwameis M,  Firbas C, Mullner M,  Putnak RJ, Thomas SJ, et al.
Immunogenicity, safety, and tolerability of a recombinant measles-virus-
based chikungunya vaccine: a randomised, double-blind, placebo-controlled,
active-comparator, ﬁrst-in-man trial. Lancet Infect Dis 2015;15(5):519–27.
101] Raviprakash K, Wang D, Ewing D, Holman DH, Block K, Woraratanadharm
J,  et al. A tetravalent dengue vaccine based on a complex adenovirus vector
provides signiﬁcant protection in rhesus monkeys against all four serotypes
of  dengue virus. J Virol 2008;82(14):6927–34.
102] Widman DG, Frolov I, Mason PW.  Third-generation ﬂavivirus vaccines
based on single-cycle, encapsidation-defective viruses. Adv Virus Res
2008;72:77–126.
103] Suzuki R, Winkelmann ER, Mason PW.  Construction and characterization of a
single-cycle chimeric ﬂavivirus vaccine candidate that protects mice against
lethal challenge with dengue virus type 2. J Virol 2009;83(4):1870–80.3 (2015) 7091–7099 7099
[104] Maves RC, Ore RM, Porter KR, Kochel TJ. Immunogenicity and protective efﬁ-
cacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus
nancymaae monkeys. Vaccine 2011;29(15):2691–6.
[105] Raviprakash K, Sun P, Raviv Y, Luke T, Martin N, Kochel T. Dengue virus photo-
inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen
compound (4′-aminomethyl-trioxsalen) is highly immunogenic in mice. Hum
Vaccines Immunother 2013;9(11):2336–41.
[106] Robert Putnak J, Coller BA, Voss G, Vaughn DW,  Clements D, Peters I,
et  al. An evaluation of dengue type-2 inactivated, recombinant subunit, and
live-attenuated vaccine candidates in the rhesus macaque model. Vaccine
2005;23(35):4442–52.
[107] Briggs CM,  Smith KM,  Piper A, Huitt E, Spears CJ, Quiles M,  et al. Live attenuated
tetravalent dengue virus host range vaccine is immunogenic in African green
monkeys following a single vaccination. J Virol 2014;88(12):6729–42.
[108] Li Z, Yang H, Yang J, Lin H, Wang W,  Liu L, et al. Construction and pre-
liminary investigation of a novel dengue serotype 4 chimeric virus using
Japanese encephalitis vaccine strain SA14-14-2 as the backbone. Virus Res
2014;191:10–20.
[109] Li XF, Deng YQ, Yang HQ, Zhao H, Jiang T, Yu XD, et al. A chimeric dengue
virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as
backbone is immunogenic and protective against either parental virus in mice
and  nonhuman primates. J Virol 2013;87(24):13694–705.
[110] Chen L, Ewing D, Subramanian H, Block K, Rayner J, Alterson KD,  et al. A
heterologous DNA prime-Venezuelan equine encephalitis virus replicon par-
ticle boost dengue vaccine regimen affords complete protection from virus
challenge in cynomolgus macaques. J Virol 2007;81(21):11634–9.
[111] Simmons M,  Burgess T, Lynch J, Putnak R. Protection against dengue virus by
non-replicating and live attenuated vaccines used together in a prime boost
vaccination strategy. Virology 2010;396(2):280–8.
[112] Sun W,  Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH,
et al. Phase 2 clinical trial of three formulations of tetravalent live-
attenuated dengue vaccine in ﬂavivirus-naive adults. Hum Vaccin 2009;5(1):
33–40.
[113] Caufour PS, Motta MC, Yamamura AM,  Vazquez S, Ferreira II, Jabor AV, et al.
Construction, characterization and immunogenicity of recombinant yellow
fever 17D-dengue type 2 viruses. Virus Res 2001;79(1–2):1–14.
[114] Galler R, Marchevsky RS, Caride E, Almeida LF, Yamamura AM,  Jabor AV,
et  al. Attenuation and immunogenicity of recombinant yellow fever 17D-
dengue type 2 virus for rhesus monkeys. Braz J Med  Biol Res 2005;38(12):
1835–46.
[115] Mateu GP, Marchevsky RS, Liprandi F, Bonaldo MC,  Coutinho ES, Dieudonne
M,  et al. Construction and biological properties of yellow fever 17D/dengue
type 1 recombinant virus. Trans R Soc Trop Med  Hyg 2007;101(3):
289–98.
[116] Trindade GF, Marchevsky RS, Fillipis AM, Nogueira RM,  Bonaldo MC,  Acero PC,
et  al. Limited replication of yellow fever 17DD and 17D-Dengue recombinant
viruses in rhesus monkeys. An Acad Bras Cienc 2008;80(2):311–21.
[117] Azevedo AS, Goncalves AJ, Archer M, Freire MS,  Galler R, Alves AM. The syn-
ergistic effect of combined immunization with a DNA vaccine and chimeric
yellow fever/dengue virus leads to strong protection against dengue. PLoS
ONE 2013;8(3):e58357.
[118] Zlatkovic J, Stiasny K, Heinz FX. Immunodominance and functional activities
of antibody responses to inactivated West Nile virus and recombinant subunit
vaccines in mice. J Virol 2011;85(5):1994–2003.
[119] World Health Organization. NIAID/WHO workshop on heterologous
prime-boost strategies for HIV, malaria and tuberculosis vaccines; 2012
http://www.who.int/immunization/research/meetings workshops/niaid
workshop hiv malaria tb 2012/en/.
[120] World Health Organization. Heterologous prime-boost immunization in
Ebola vaccine development, testing and licensure; 2014 http://www.
who.int/immunization/research/meetings workshops/ebola primeboost
21nov14/en/.
[121] Cassetti MC,  Thomas SJ. Dengue human infection model: introduction. J Infect
Dis 2014;209(Suppl. 2):S37–9.
[122] Halstead SB. Identifying protective dengue vaccines: guide to mastering an
empirical process. Vaccine 2013;31(41):4501–7.
[123] Sariol CA, White LJ. Utility, limitations, and future of non-human primates for
dengue research and vaccine development. Front Immunol 2014;5:452.
